Recorded Presentations from the NCCN 2019 Congress Series™: Lung Cancer

The American Cancer Society (ACS) estimates that 228,150 new cases of lung cancer will be diagnosed in the United States in 2019 with an estimated 142,670 estimated deaths, with smoking remaining an important risk factor.  The emergence of new biomarker testing, advances in radiation techniques, and the availability of new systemic therapies has changed the treatment landscape for non-small cell lung cancer.  This rapid pace of development and evolution has created challenges for clinicians to remain current with the advances in treatment options and the management of adverse events resulting from these new therapies. The NCCN 2019 Congress Series™: Lung Cancer is designed to familiarize clinicians with key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), new and emerging therapeutic options, the latest clinical research on lung cancer, and how these advances compare to the current standard of care to optimize management of patients with lung cancer and assist practitioners to incorporate new cancer treatment strategies and regimens into their practice.

Target Audience

This educational program is designed to meet the educational needs of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, pharmacists, physician assistants, and other relevant health care professionals who manage the care of patients with lung cancer.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Celgene Corporation
  • Takeda Oncology

This activity is supported by a grant from Pfizer Inc.

This activity is supported by an independent educational grant from Incyte.

This project has been made possible in part by a grant from the Varian Medical Systems Educational Grant Corporate Fund, an advised fund of Silicon Valley Community Foundation.

Course summary
Course opens: 
12/17/2019
Course expires: 
12/17/2020
Cost:
$0.00

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Full disclosure of faculty relationships will be made prior to the activity.

These activities are approved for AMA PRA Category 1 Credit™ and will award contact hours for nurses, pharmacists, and other health care professionals.

Available Credit

Accreditation Period

Course opens: 
12/17/2019
Course expires: 
12/17/2020
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: